NCT04839497View on ClinicalTrials.gov

Multicenter Trial Evaluating the Safety and Efficacy of Autologous Volar Fibroblast Injection Into the Terminal Limb of Amputees.

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

August 1, 2026

Study Completion Date

January 1, 2027

Conditions
Amputation
Interventions
COMBINATION_PRODUCT

Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees

Autologous Volar Fibroblasts Treatment- harvested from patient's biopsied volar skin. Intradermal injection of Volar fibroblasts in the residual limb of transtibial amputees.

Trial Locations (1)

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Major Extremity Trauma Research Consortium

OTHER